CN

RESEARCH

UPCOMING PRODUCTS
  • Recombinant Tuberculosis Vaccine

    The recombinant tuberculosis vaccine (AEC/BCO2) developed by Zhifei is composed of recombinant mycobacterium tuberculosis protein expressed in E. coli and novel biological adjuvant system developed by the company and is produced after purification and lyophilization. It is indicated for the prevention of latent tuberculosis infection (LTBI).

  • Influenza Virus Split Vaccine

    The influenza virus split vaccine developed by Zhifei is made by inoculating chicken embryos with WHO-recommended influenza virus strains, and is prepared by culture, inactivation and purification. It has low protein, low egg albumin residue and low endotoxin, which is safer to use.

  • Recombinant Mycobacterium Tuberculosis Fusion Protein (EC)

    Recombinant mycobacterium tuberculosis fusion protein (EC) is based on specific ESAT6 and CFP10 protein secreted in the early stage of the growth process of Mycobacterium tuberculosis (M. tuberculosis). The two proteins are fused and expressed by genetic engineering and will be used clinically for the diagnosis of people with M. tuberculosis infection and for identification of BCG vaccination and M. tuberculosis infection. The product has high specificity, sensitivity and is easy to use thus providing a safe, effective and economical solution for the detection of M. tuberculosis infection.

  • MenACYW135 conjugate vaccine

    This candidate is developed based on the marketed product — MenACYW135 polysaccharide vaccine, with tetanus toxoid as the protein carrier. It is indicated for infants and children aged 3 months and above to prevent infectious disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135, providing earlier protection for younger infants and toddlers.

  • 15-valent Pneumococcal conjugate vaccine (PCV15)

    This candidate is indicated for active immunization to prevent invasive disease caused by 15 serotypes of Streptococcus pneumoniae included in this vaccine. This candidate is the first of its kind — comparing with PCV13, it covers two extra serotypes that are prevalent among Chinese population and thus having a broader protection. This project has been supported by the nation’s Major Project of New Medicine Development.

  • Shigella vaccine (bivalent)

    The bivalent shigella vaccine the company is developing is indicated for the prevention of bacterial shigella caused by shigella flexneri and shigella sonnei. It is the first conjugate vaccine developed that can prevent infections caused by both shigella flexneri and shigella sonnei. This Class I New Drug is supported by the nation’s Major Project of New Medicine Development and is protected by multiple patents.

  • EV71 inactivated vaccine

    This candidate is indicated for infants and children aged 6 months and above. After injection, the vaccine can stimulate the body to generate immunity against enterovirus 71 to prevent hand, foot and mouth’s disease caused by this virus.